Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin

Douglas K. Marks; John Kucharczyk; Pan Kim; Donian I. Chyong; Robyn D. Gartrell; Yan Lu; Hanina Hibshoosh; Hua Guo; Thomas R.Jeffry Evans; Juanita Lopez; Rebecca Kristeleit; Eileen Connolly; Yvonne Saenger; Kevin Kalinsky

doi:10.1080/07357907.2021.1938109

Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin

Douglas K. Marks, John Kucharczyk, Pan Kim, Donian I. Chyong, Robyn D. Gartrell, Yan Lu, Hanina Hibshoosh, Hua Guo, Thomas R.Jeffry Evans, Juanita Lopez, Rebecca Kristeleit, Eileen Connolly, Yvonne Saenger, Kevin Kalinsky

Research output: Contribution to journal › Article › peer-review

Abstract

Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.

Original language	English (US)
Pages (from-to)	466-472
Number of pages	7
Journal	Cancer Investigation
Volume	39
Issue number	6-7
DOIs	https://doi.org/10.1080/07357907.2021.1938109
State	Published - 2021
Externally published	Yes

Keywords

EMT
Eribulin
Eribulin-LF
Metastatic breast cancer
metastatic ovarian cancer
phase I clinical trial
quantitative multiplex immunofluorescence
tumor immunobiology
tumor microenvironment

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2021.1938109

Fingerprint

Dive into the research topics of 'Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin'. Together they form a unique fingerprint.

Cite this

Marks, D. K., Kucharczyk, J., Kim, P., Chyong, D. I., Gartrell, R. D., Lu, Y., Hibshoosh, H., Guo, H., Evans, T. R. J., Lopez, J., Kristeleit, R., Connolly, E., Saenger, Y., & Kalinsky, K. (2021). Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. Cancer Investigation, 39(6-7), 466-472. https://doi.org/10.1080/07357907.2021.1938109

Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. / Marks, Douglas K.; Kucharczyk, John; Kim, Pan et al.
In: Cancer Investigation, Vol. 39, No. 6-7, 2021, p. 466-472.

Research output: Contribution to journal › Article › peer-review

Marks, DK, Kucharczyk, J, Kim, P, Chyong, DI, Gartrell, RD, Lu, Y, Hibshoosh, H, Guo, H, Evans, TRJ, Lopez, J, Kristeleit, R, Connolly, E, Saenger, Y & Kalinsky, K 2021, 'Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin', Cancer Investigation, vol. 39, no. 6-7, pp. 466-472. https://doi.org/10.1080/07357907.2021.1938109

@article{ecb4b1aacd8149e5bc30c4d6ffa5de76,

title = "Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin",

abstract = "Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.",

keywords = "EMT, Eribulin, Eribulin-LF, Metastatic breast cancer, metastatic ovarian cancer, phase I clinical trial, quantitative multiplex immunofluorescence, tumor immunobiology, tumor microenvironment",

author = "Marks, {Douglas K.} and John Kucharczyk and Pan Kim and Chyong, {Donian I.} and Gartrell, {Robyn D.} and Yan Lu and Hanina Hibshoosh and Hua Guo and Evans, {Thomas R.Jeffry} and Juanita Lopez and Rebecca Kristeleit and Eileen Connolly and Yvonne Saenger and Kevin Kalinsky",

note = "Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/07357907.2021.1938109",

language = "English (US)",

volume = "39",

pages = "466--472",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "6-7",

}

TY - JOUR

T1 - Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin

AU - Marks, Douglas K.

AU - Kucharczyk, John

AU - Kim, Pan

AU - Chyong, Donian I.

AU - Gartrell, Robyn D.

AU - Lu, Yan

AU - Hibshoosh, Hanina

AU - Guo, Hua

AU - Evans, Thomas R.Jeffry

AU - Lopez, Juanita

AU - Kristeleit, Rebecca

AU - Connolly, Eileen

AU - Saenger, Yvonne

AU - Kalinsky, Kevin

PY - 2021

Y1 - 2021

N2 - Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.

AB - Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.

KW - EMT

KW - Eribulin

KW - Eribulin-LF

KW - Metastatic breast cancer

KW - metastatic ovarian cancer

KW - phase I clinical trial

KW - quantitative multiplex immunofluorescence

KW - tumor immunobiology

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85108261957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108261957&partnerID=8YFLogxK

U2 - 10.1080/07357907.2021.1938109

DO - 10.1080/07357907.2021.1938109

M3 - Article

C2 - 34075851

AN - SCOPUS:85108261957

SN - 0735-7907

VL - 39

SP - 466

EP - 472

JO - Cancer Investigation

JF - Cancer Investigation

IS - 6-7

ER -

Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this